0.9049

1.59% -0.0146

After Hours: .92 0.0151 +1.67%

Nautilus Biotechnology Inc (NAUT)

Overview News Price History Option Chain Financials Discussions Forecast

Nautilus Biotechnology Inc stock is traded at $0.9049, with a volume of 575.75K. It is down -1.59% in the last 24 hours and down -8.16% over the past month. Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.

Previous Close:

$0.9195

Open:

$0.9077

24h Volume:

575.75K

Relative Volume:

0.67

Market Cap:

$115.15M

Revenue:

Net Income/Loss:

$-57.09M

P/E Ratio:

-2.0033

EPS:

-0.4517

Net Cash Flow:

$-51.43M

1W Performance:

+2.17%

1M Performance:

-8.16%

6M Performance:

-65.46%

1Y Performance:

+38.83%

1-Day Range:

$0.89

$0.9498

1-Week Range:

$0.89

$0.99

52-Week Range:

$0.6519

$4.3101

Nautilus Biotechnology Inc Stock (NAUT) Company Profile

Name

Nautilus Biotechnology Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

206-333-2001

Address

2701 EASTLAKE AVE EAST, SEATTLE

Employee

130

Twitter

Next Earnings Date

2026-10-26

Latest SEC Filings

NAUT's Discussions on Twitter

Compare NAUT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAUT Nautilus Biotechnology Inc	0.9049	114.82M	0	-57.09M	-51.43M	-0.4517
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-24	Downgrade	Goldman	Neutral → Sell
Jun-27-24	Initiated	Guggenheim	Buy
Jun-03-24	Resumed	Jefferies	Hold
Jan-06-22	Initiated	Morgan Stanley	Equal-Weight
Nov-02-21	Initiated	Cowen	Outperform
Aug-04-21	Initiated	Goldman	Neutral
Jul-13-21	Initiated	Jefferies	Buy

View All

Nautilus Biotechnology Inc Stock (NAUT) Latest News

Sep 04, 2026

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms - investingnews.com

Sep 04, 2026

Nautilus Biotechnology paper on tau proteoform analysis published in Nature Methods - tradersunion.com

Sep 04, 2026

Sep 02, 2026

Nautilus Biotechnology (NAUT) Advances 3.81% to $0.96, Testing Move Toward Key $1.01 ResistanceHigh Reward Trades - siam.in

Sep 02, 2026

Nautilus Biotechnology heads to HUPO 2026 to unveil Voyager platform breakthroughs - Traders Union

Sep 02, 2026

Aug 28, 2026

Andreessen Horowitz sells Nautilus (NAUT) shares around $1 - Stock Titan

Aug 28, 2026

Aug 24, 2026

Nautilus (NAUT) Market: Finishes 8.30% Down at $0.88 in the Latest Session; Price Levels: the Session Ends Within the Reported Technical BoundariesValue Area Low - vinanet.vn

Aug 24, 2026

Nautilus (NAUT) Financial Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Trading Move - vinanet.vn

Aug 24, 2026

Aug 21, 2026

Nautilus Biotechnology urges new methods to address biological validation challenge in proteomics - Traders Union

Aug 21, 2026

Aug 19, 2026

Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionSystematic Flow - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat

Aug 18, 2026

Aug 14, 2026

Nautilus Biotechnology Earnings Call Balances Promise and Risk - TipRanks

Aug 14, 2026

NAUT Q2 2026 Earnings: Narrower Loss Surprise Lifts Shares 22%Earnings Deceleration Risk - vinanet.vn

Aug 14, 2026

Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A - Stock Titan

Aug 14, 2026

Aug 11, 2026

Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support LevelImbalance Zone - dars.gov.et

Aug 11, 2026

Aug 10, 2026

Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsMAMA Signal - dars.gov.et

Aug 10, 2026

Aug 07, 2026

Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - Kalkine

Aug 07, 2026

Nautilus Biotechnology (NAUT) Institutional Ownership 2026 - MarketBeat

Aug 07, 2026

Aug 06, 2026

Nautilus Biotechnology unveils new proteomics approach for dementia studies - Traders Union

Aug 06, 2026

Aug 03, 2026

Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha

Aug 03, 2026

Jul 31, 2026

Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT - TradingView

Jul 31, 2026

Jul 30, 2026

Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Rises By 74.6% - MarketBeat

Jul 30, 2026

Jul 29, 2026

Nautilus Biotechnology sets 31 July deadline for Iterative Mapping Grant Program applications - tradersunion.com

Jul 29, 2026

Jul 28, 2026